Lipocine Inc. (LPCN)
1.4100 -0.05 (-3.42%)
After hours: 7:28PM EDT
Chart Events
Performance Outlook
| Previous Close | 1.4700 |
| Open | 1.4700 |
| Bid | 1.4300 x 1000 |
| Ask | 1.4500 x 3200 |
| Day's Range | 1.4150 - 1.5099 |
| 52 Week Range | 0.4300 - 2.4200 |
| Volume | 1,333,161 |
| Avg. Volume | 5,196,026 |
| Market Cap | 128.904M |
| Beta (5Y Monthly) | 0.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks Small Cap Research
LPCN: Lipocine’s LiFT Results: A Comparison with Peers
By John Vandermosten, CFA NASDAQ:LPCN Positive Topline Phase II Results from Ongoing LiFT Study, Update Includes Comparison Lipocine Inc. (NASDAQ:LPCN) announced positive topline data from LiFT (1), a Phase II study of its candidate LPCN 1144 in biopsy-confirmed, non-cirrhotic male NASH patients with F1-F3 fibrosis. LiFT reported that both treatment arms met the primary endpoint with a high
- Zacks Small Cap Research
LPCN: LiFT: Twelve-week Topline Touts Statistical Significance
By John Vandermosten NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Positive Topline Phase II Results from Ongoing LiFT Study Lipocine Inc. (NASDAQ:LPCN) announced positive topline data from LiFT (1), a Phase II study of its candidate LPCN 1144 in biopsy-confirmed, non-cirrhotic male Non-alcoholic Steatohepatitis (NASH) patients with F1-F3 fibrosis. LiFT reported that both treatment arms met the
- Zacks Small Cap Research
LPCN: Tentative Approval Granted, Target Up
By John Vandermosten NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT FDA Grants Tentative Approval to Tlando After multiple extensions from the August 2020 target action date, the FDA granted tentative approval of Lipocine’s (NASDAQ: LPCN) Tlando on December 8th. Tlando met all required quality, safety and efficacy standards necessary for approval; however, marketing of Tlando will not be allowed
